An oncology leader views AI's most powerful near-term application as handling tedious logistical and bureaucratic tasks, not discovering novel molecules. By automating paperwork and trial planning, AI can liberate scientists to spend more time on deep, creative thinking that drives breakthroughs.

The most significant opportunity for AI in healthcare lies not in optimizing existing software, but in automating 'net new' areas that once required human judgment. Functions like patient engagement, scheduling, and symptom triage are seeing explosive growth as AI steps into roles previously held only by staff.

Clinical trial delays stem not from slow individual tasks but from the handoffs, reviews, and data transfers between them. Agentic AI's primary benefit is orchestrating these fragmented workflows, addressing the root cause of inefficiency by connecting previously siloed steps and reducing manual interventions.

AI adoption in drug companies isn't about moonshot discovery via a single prompt. Its immediate, high-impact use is in automating and error-proofing massive regulatory documents for the FDA, where a single misplaced comma can cause costly, multi-billion dollar delays.

While AI-driven drug discovery is the ultimate goal, Titus argues its most practical value is in improving business efficiency. This includes automating tasks like literature reviews, paper drafting, and procurement, freeing up scientists' time for high-value work like experimental design and interpretation.

AI will create jobs in unexpected places. As AI accelerates the discovery of new drugs and medical treatments, the bottleneck will shift to human-centric validation. This will lead to significant job growth in the biomedical sector, particularly in roles related to managing and conducting clinical trials.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

AI's role in bioprocessing is not to replace scientists but to augment their abilities. It serves as a powerful tool providing predictive insights and autonomous optimizations. The ideal future is a partnership where humans guide strategy and interpret results, while AI handles the complex data analysis to make processes faster and more reliable.

For years, the industry managed rising trial complexity by adding more people and process controls. This model is no longer scalable. The current push for automation is a response to this inflection point, as new AI technology is finally capable of participating in workflows rather than just supporting isolated tasks.